Over the past 20 years, there has been a shift from vitamin K antagonists to direct oral
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …

The direct oral anticoagulants (DOACs), or non-vitamin K antagonist oral anticoagulants
(NOACs), including dabigatran, which inhibits thrombin, as well as rivaroxaban, apixaban …

Non‐vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor
dabigatran and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and …

Direct oral anticoagulants (DOACs) include dabigatran etexilate, a direct thrombin inhibitor,
and specific inhibitors of activated coagulation factor X (FXa; eg apixaban, betrixaban …

The direct oral anticoagulants (DOACs), which include dabigatran, rivaroxaban, apixaban,
and edoxaban, are licensed for stroke prevention in patients with atrial fibrillation and for …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which
inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit …

Essentials• There remains clinical concern regarding the optimal management of direct oral
(DOAC) anticoagulant effect for emergencies such as bleeding or urgent …

Oral anticoagulants, old and new, are effective therapies for prevention and treatment of
venous thromboembolism and reduction of stroke risk in patients with atrial fibrillation …

In the last decade, several direct oral anticoagulants (DOAC; dabigatran, rivaroxaban,
apixaban, edoxaban) have been marketed for prophylaxis and/or treatment of …